Literature DB >> 19056039

Family cancer syndromes: inherited deficiencies in systems for the maintenance of genomic integrity.

Huferesh Darbary1, Daniel L Stoler, Garth R Anderson.   

Abstract

Familial cancer syndromes have revealed important fundamental features regarding how all cancers arise through destabilization of the genome, such that somatic evolution can select for the disruption of critical cellular coordinating and regulatory features. The authors examine those cellular genes and systems whose normal role is to preserve genomic integrity and relate them to the genetic foundations of heritable cancers. By examining how these cellular systems normally function, how family cancer genes are able to affect the process of tumor progression can be learned. In so doing, a clearer picture of how sporadic cancers arise is additionally gained.

Entities:  

Mesh:

Year:  2009        PMID: 19056039      PMCID: PMC2614132          DOI: 10.1016/j.soc.2008.08.001

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  107 in total

Review 1.  Transcription-coupled repair and human disease.

Authors:  P C Hanawalt
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

2.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

3.  Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II.

Authors:  R Drapkin; J T Reardon; A Ansari; J C Huang; L Zawel; K Ahn; A Sancar; D Reinberg
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

4.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

5.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

Authors:  S Markowitz; J Wang; L Myeroff; R Parsons; L Sun; J Lutterbaugh; R S Fan; E Zborowska; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

6.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

7.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.

Authors:  F S Leach; N C Nicolaides; N Papadopoulos; B Liu; J Jen; R Parsons; P Peltomäki; P Sistonen; L A Aaltonen; M Nyström-Lahti
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

8.  Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4.

Authors:  F K Chan; J Zhang; L Cheng; D N Shapiro; A Winoto
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

9.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.

Authors:  G J Hannon; D Beach
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

10.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.

Authors:  K L Guan; C W Jenkins; Y Li; M A Nichols; X Wu; C L O'Keefe; A G Matera; Y Xiong
Journal:  Genes Dev       Date:  1994-12-15       Impact factor: 11.361

View more
  2 in total

1.  Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Jan Samuelsson; Ola Landgren
Journal:  Genome Med       Date:  2009-05-29       Impact factor: 11.117

2.  Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.

Authors:  Ubaldo E Martinez-Outschoorn; Renee M Balliet; Zhao Lin; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-10-09       Impact factor: 4.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.